Answers are grounded in this paper and cite their sources.
PURPOSE: To report the successful use of tofacitinib in the treatment of refractory uveitis and scleritis. OBSERVATIONS: Two patients, one with scleritis and another with anterior and intermediate uveitis, presented with refractory disease after failure of multiple steroid-sparing therapies. Treatment with tofacitinib led to durable resolution of uveitis and scleritis. CONCLUSIONS AND IMPORTANCE: Tofacitinib is a potential novel treatment option for refractory, noninfectious inflammatory eye disease.
No takes yet. Share an insight, caveat, or question.
Paley et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: